Purpose
To assess the implementation of Digital Therapeutics in the care of cancer patients and survivors by synthesising the best available evidence regarding their efficacy in improving health outcomes compared to usual care or placebo control groups.
Methods
In this systematic review and meta-analysis, a comprehensive search of literature published between 2018 and 2023 was conducted in PubMed, Embase, Medline, CINAHL, Web of Science, Scopus, Google Scholar, WHO Publications, ISRCTN, and ClinicalTrials.gov. Randomised controlled trials published in English were eligible for inclusion if they employed Digital Therapeutics to treat adult cancer patients and survivors. Two independent reviewers conducted the database searches, data extraction, and risk of bias assessment according to Cochrane's guidelines. Meta-analyses were conducted using the RevMan Web software. This systematic review was registered with PROSPERO CRD42023491190.
Results
Twenty studies met the inclusion criteria. Digital Therapeutics demonstrated a significant reduction in fear of cancer recurrence (SMD = −0.43, p < 0.00001) and in fatigue (SMD = −0.23, p = 0.0005). Additionally, there was a significant reduction in Depression (SMD = −0.37, p < 0.00001) and Anxiety (SMD = −0.32, p = 0.0002) symptoms, along with significant improvements in Quality of Life (SMD = 0.23, p = 0.002) from Digital Therapeutics use. No publication bias was detected.
Conclusion
Given their benefits, the continued development of Digital Therapeutics for cancer patients and survivors is warranted. Future research should explore the geographical and socio-demographic influences on the accessibility of such interventions to meet the diverse needs of cancer populations worldwide.
扫码关注我们
求助内容:
应助结果提醒方式:
